Lynk Pharmaceuticals Co., Ltd. has initiated dosing in its Phase II clinical trial evaluating LNK01004, a topical pan-JAK inhibitor, for the treatment of adult patients with non-segmental vitiligo.

• Trial Objective: The multicentre, randomised, double-blind, vehicle-controlled Phase II study is evaluating the efficacy and safety of LNK01004 ointment in adults with non-segmental vitiligo.
• Mechanistic Design: LNK01004 is a novel, topically applied pan-JAK inhibitor designed with skin-restricted distribution to minimise systemic exposure while targeting inflammatory signalling pathways.
• Clinical Milestone: The first patient has been dosed, advancing LNK01004 into Phase II clinical evaluation for non-segmental vitiligo.

This summary is based on a press release issued by Lynk Pharmaceuticals Co., Ltd. via PR Newswire.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.